Dna Fragmentation Factor 40-Based Therapeutic Approaches for Cancer: A Review Article Publisher Pubmed

Summary: Could boosting DFF40 push cancer cells toward apoptosis? A review notes low DFF40 in some tumors and explores gene-therapy-based replacement. #CancerResearch #MolecularOncology

Masaeli F¹ ; Omoomi S¹ ; Shafiee F^{1, 2}
Source: Medical Oncology Published:2024

Abstract

DNA Fragmentation Factor (DFF) is a heterodimer protein involved in DNA fragmentation during apoptosis, which acts as a trigger downstream of caspase-3 activation. DFF40 catalytically active homo-oligomers break down chromosomal DNA. Previous scientific investigations have revealed a link between DFF40 expression changes and various cancers. DFF40 deletion or down-regulation has been observed in some cancers. Consequently, therapeutic strategies involving the DFF40 molecule compensating led to an increased rate of cancer cell apoptosis. In this review article, we aimed to introduce cancers with low expression of this protein first. The second part of this paper focuses on studies that utilized exogenous DFF40 protein produced by recombinant DNA technology and surveyed during in vitro and in vivo tests. Finally, compensation for diminished expression of the mentioned protein via gene therapy-based techniques to make up for this apoptotic molecule’s low expression is the topic of the last part of this review article. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.